Learning Hub

< BACK iPROLEPSIS digital ecosystem's architecture Oct 5, 2023 iPROLEPSIS ecosystem's architecture: a glimpse into technical progress One of the main objectives of the iPROLEPSIS project is to provide a digital health ecosystem to support healthcare professionals in disease screening, monitoring, and treatment while empowering individuals with/at risk of Psoriatic Arthritis with personalised insights and preventive interventions. In September 2023, the project’s technical partners introduced the first version of the iPROLEPSIS ecosystem architecture , including the initial technical specifications and product backlog. __________________ Amalia Ntemou from Netcompany-Intrasoft , consortium partner leading technical specification, system architecture and product backlog task within iPROLEPSIS, shares insights on the latest updates on the iPROLEPSIS ecosystem architecture. The first version of the iPROLEPSIS ecosystem's architecture and technical specifications has been defined. Can you explain the importance of this achievement in the project's development process? One of the main objectives of the iPROLEPSIS project is to provide a digital health ecosystem to support healthcare professionals in disease screening, monitoring, and treatment, while empowering individuals with/at risk of PsA with personalised insights and preventive interventions. The design of the architecture and the definition of functional and non-functional requirements are essential for the successful implementation of the iPROLEPSIS ecosystem as it constitutes a clear and comprehensive guide for partners’ development efforts. Various systems’ elements, components, connectors, processes and interactions are illustrated thereby enabling common understanding among project’s partners and adherence to common approaches and specifications that promote effective collaboration and delivery. A well-defined architecture with clear functional and non-functional requirements can be the basis for delivering sustainable solutions. What are the main components of the iPROLEPSIS digital ecosystem to be developed? The initial conceptual architecture of the iPROLEPSIS ecosystem consists of the miPROLEPSIS patient mobile app (including the embedded subcomponent/feature biAURA), the iPROLEPSIS healthcare professionals (HCP) web app , the cloud-based Data Management System , the AI-driven Lifestyle Recommendation Engine , the xAI-driven Models Engine and the Serious Games Suite . Finally, the operation of the entire system is supported by the Orchestration and Monitoring component . For whom is the iPROLEPSIS ecosystem specifically intended, and how does it cater to their unique needs? Patients are the primary users of the miPROLEPSIS patient app which is the tool for personalised disease monitoring. The miPROLEPSIS patient app operates as a tool for capturing data from sensors and wearable devices, as well as communicating feedback from the recommendation engine to the user. The miPROLEPSIS patient app incorporates additional applications/features (e.g., biAURA, keyboard etc.) for further monitoring of patients’ conditions, interventions and engagement hooks. Via the miPROLEPSIS HCP app, doctors and health care professionals are able to track their patients’ health status, review projections of the PsA progression, and utilise recommendations of optimised personalised suggestions towards a better management of PsA. Aggregated patients’ data about their health status, and outcomes of the xAI Models Engine are displayed intuitively and informatively to HCPs through dashboards. Doctors can monitor patients’ adherence to medical, dietary, and physical activity plans and issue warnings and notifications or adjust treatment regimens. In this way, accurate interventions are supported, while efficient and optimized management of PsA patients’ needs can be achieved and communicated to fellow colleagues and related stakeholders. What was the main focus while designing the iPROLEPSIS ecosystem architecture? The iPROLEPSIS digital health ecosystem serves as the enabler for personalised preventive care and the empowerment of citizens, patients and Healthcare Professionals (HCP). This emphasis on personalisation and empowerment guided the collection and definition of functional and non-functional requirements, as well as the internal architecture of components and technical specifications. Ultimately, these efforts led to the design of the ecosystem’s architecture. Have any methodologies been used in designing the iPROLEPSIS ecosystem architecture, and why is it important to use them? To organise the design and architecture of the iPROLEPSIS ecosystem, several established frameworks/methodologies were evaluated based on a thorough literature review in order to conclude to a framework that provides a holistic and comprehensive view of a software system’s architecture. Finally, we used a widely known methodology developed in 1995 by Kruchten , due to its ability to offer a structured approach to the system’s design, enabling multidisciplinary teams to represent different aspects of the system effectively and in detail. Utilising already established methodologies and following best practices, enhances efficiency, reduces risks, leads in better design decisions and contributes to overall success of the project. As the project progresses, how will the architecture and product backlog be refined and adapted during the development phases of the iPROLEPSIS? Development and establishment of the iPROLEPSIS digital health ecosystem is an ongoing process that runs approximately until the end of the project. Technical testing and verification of new versions of ecosystem’s components, as well as the monitoring of their performance and stability once released to users, have also been considered. The outcomes of development and monitoring processes will continuously populate the product backlog, representing the changing needs and priorities as the development of the components progresses. All updates and enhancements will lead to a refined version of the architecture and a fully operational iPROLEPSIS ecosystem. Stay tuned as we embark on this transformative journey towards a brighter future in Psoriatic Arthritis management! News & Events iPROLEPSIS - news.png News & Events iPROLEPSIS - news.png 1/1 PREVIOUS NEXT

< BACK Call for Workshop Papers: AI-enabled Digital Health Tools for Non-Communicable Diseases: From Concepts to Impact May 16, 2025 A joint workshop by iPROLEPSIS and AI-PROGNOSIS at IEEE HealthCom 2025 in Abu Dhabi, focusing on AI-enabled Digital Health Tools for Non-Communicable Diseases The iPROLEPSIS and AI-PROGNOSIS projects are co-organising a workshop titled: “AI-enabled Digital Health Tools for Non-Communicable Diseases: From Concepts to Impact” as part of the IEEE HealthCom 2025 conference , taking place on 21–23 October 2025 in Abu Dhabi, United Arab Emirates. More information: https://healthcom2025.ieee-healthcom.org/program/ai-enabled-digital-health-tools-non-communicable-diseases-concepts-impact We invite authors to submit original research, position papers, or case studies with practical insights. Topics of interest include (but are not limited to): Predictive models for early detection, risk assessment, and prognosis of NCDs Digital biomarkers and wearable sensors for NCDs Machine learning for personalized treatment, disease management, and precision medicine AI in remote care, mHealth, and telemedicine for NCDs Regulatory and ethical considerations in AI-enabled software as medical device Data quality, fairness, and explainability in AI health applications User-centered design in AI-enabled health technology for chronic conditions Translational pathways from research prototypes to scalable digital health solutions The workshop aims to feature 10 selected papers. Important dates: Workshop paper submission July 1, 2025 Acceptance notifications August 15, 2025 Camera Ready papers August 30, 2025 For any questions, please contact: Dr. Vasileios Charisis , Aristotle University of Thessaloniki, Greece – vaschar@auth.gr Dr. Stelios Hadjidimitriou , Aristotle University of Thessaloniki, Greece – shadjidim@ece.auth.gr HealthCom 2025_Call for WS papers_Digital Health Tools for NCDs .pdf Download PDF • 181KB iPROLEPSIS_Call for workshop papers.png iPROLEPSIS_Call for workshop papers.png 1/1 PREVIOUS NEXT

< BACK iPROLEPSIS presented at MEDICA 2023 Nov 14, 2023 iPROLEPSIS project presented at the world’s largest event for the medical sector Project partners Amalia Ntemou ( Netcompany-Intrasoft ) and Georgios Apostolidis ( Aristotle University of Thessaloniki (AUTH) ) presented the iPROLEPSIS project at the MEDICA - Leading International Trade Fair in Germany. MEDICA is the world’s largest event for the medical sector. It attracts several thousand exhibitors from more than 50 countries in the halls. Furthermore, each year, leading individuals from business, research, and politics grace this top-class event with their presence. MEDICA 2023 took place on 13-16 November in Düsseldorf, Germany. IMG_20231115_135346.jpg IMG_20231115_135346.jpg 1/1 PREVIOUS NEXT

< BACK iPROLEPSIS presented at PhD DEI 2023 Nov 13, 2023 Highlights from PhD DEI 2023 Organised by the Universidade de Lisboa (the Instituto Superior Técnico), the PhD DEI 2023 event on 10 November 2023 served as a platform for introducing new PhD students to the Department of Engineering and Informatics (DEI). The event fostered an environment of knowledge-sharing and collaboration among students from the Doctoral Program in Computer Science and Engineering and the Doctoral Program in Digital Media. One of the standout presentations at PhD DEI 2023 was the poster presentation on the iPROLEPSIS Exergames. This presentation, delivered by Bárbara Ramalho, a PhD student from the FMH-ULisboa team, highlighted the general concepts and objectives of the iPROLEPSIS project. The iPROLEPSIS Exergames were developed through a co-design process, emphasizing collaborative and innovative approaches to game design aimed at promoting physical activity and health. Read more: We now know the audience's favorite posters from PhD DEI 2023! - Departamento de Engenharia Informática (DEI) ( ulisboa.pt ) 1/1 PREVIOUS NEXT

< BACK Initiation of the iPROLEPSIS-PDPID Study Oct 22, 2024 Initiating Patient Enrollment for Psoriatic Arthritis Research The PsA digital phenotyping and inflammation drivers study (iPROLEPSIS-PDPID) has officially been initiated. The first patient was enrolled in the Netherlands in early September. The iPROLEPSIS-PDPID study focuses on using smart devices and clinical data to develop AI-driven models for personalised monitoring and flare prediction. This approach aims to empower patients by providing tools to better understand their condition. The study seeks to develop unobtrusive and affordable digital biomarkers capable of detecting changes in disease activity, including flares, and identifying their triggers in patients with psoriatic arthritis (PsA). The study is being conducted in four countries: the Netherlands, the UK, Portugal, and Greece. Patient recruitment is planned to start in the UK by the end of October, with recruitment in Greece and Portugal expected later this year. The miPROLEPSIS phone app is used in this study. The app is installed on patients' smartphones and acts as a data collection tool, which will be used to develop and train algorithms. The app measures physical activity, sleep duration, self-registered flares, and daily records of pain, fatigue, sleep quality, and morning stiffness. Additionally, the Garmin Vivoactive 5 smartwatch is used to collect data on physical activity, heart rate, heart rate variability, and sleep quality. 1/1 PREVIOUS NEXT

Learning Hub Explore resources to help you understand and manage psoriatic arthritis. Learning hub Key Facts Handbook News Feed Quizzes Search How will psoriatic arthritis affect me? Work See related Handbook section PREVIOUS NEXT

< BACK iPROLEPSIS presented to Eli Lilly in the Netherlands Nov 8, 2023 Presentation to Eli Lilly introduces iPROLEPSIS as the next step in personalised psoriatic arthritis care On the 7th of November 2023, Ilja Tchetverikov from CICERO Rheumatology presented the results and prospects of the DEPAR cohort and introduced iPROLEPSIS clinical studies to the representatives of Eli Lilly company in the Netherlands. DEPAR, Dutch south-west Psoriatic Arthritis Registry, is a registry set up by Cicero Rheumatology, a partnership of rheumatologists working in 15 different hospitals in the south-west of the Netherlands. DEPAR, with the participation of well over 900 patients, supports rheumatologists to gain insight into the treatment and course of psoriatic arthritis. The presentation highlighted iPROLEPSIS as a logical next step in the further development of DEPAR, emphasising the project’s vision and aim to explain psoriatic arthritis inflammation through multi-source data analysis, guiding to a novel personalised digital care ecosystem. Slide1.JPG Slide2.JPG Slide6.JPG Slide1.JPG 1/6 PREVIOUS NEXT

< BACK iPROLEPSIS Website Goes Live Mar 26, 2023 The website of the iPROLEPSIS project is finalised and available online. The website of the iPROLEPSIS project is finalised and available online. The website presents the key facts and figures about the project, and will be frequently updated about the project results, events, and key plans. News & Events iPROLEPSIS - news.png News & Events iPROLEPSIS - news.png 1/1 PREVIOUS NEXT

< BACK European Researchers' Night Sep 30, 2024 Engaging Communities through Science Bárbara Ramalho, Hugo Escobar, and Marta Vicente from FMH/IST-ULisboa presented the iPROLEPSIS Games and the iPROLEPSIS project at the European Researchers' Night in Oeiras, Portugal. This event, part of the "Science for Everyone (SCIEVER) – Inclusion and Sustainability" initiative, aimed to engage the public with scientific advancements. Researchers from various fields participated, sharing their work through interactive presentations, live demonstrations, and diverse activities, fostering a stronger connection between science and the community. The event unerlined the importance of making scientific research accessible to all. 1/4 PREVIOUS NEXT

< BACK Seasons Greetings from iPROLEPSIS Dec 20, 2024 Happy holidays and best wishes for the year ahead! As the year comes to a close, we at the iPROLEPSIS consortium wish you warmth, joy, good health, and peace. Your support and engagement mean so much to us. Thank you for being part of our journey! Happy holidays and best wishes for the year ahead! 1/1 PREVIOUS NEXT

< BACK Understanding Patient Perspectives on Digital Biomarkers for Psoriatic Arthritis Nov 28, 2024 A new study explores opportunities and challenges in using digital biomarkers for Psoriatic Arthritis management A recently published study, Digital biomarkers for psoriatic arthritis: a qualitative focus group study on patient-perceived opportunities and barriers , examines how patients with Psoriatic Arthritis (PsA) perceive the use of digital biomarkers (dBMs) in managing their condition. With the increasing use of wearables like smartphones and smartwatches, there is growing interest in utilizing these tools to track physiological and behavioral data in everyday life. This study, involving 27 PsA patients across six focus groups, sheds light on the potential benefits and limitations of integrating dBMs into PsA care. Key Insights The study identified three main areas of interest: Opportunities: Patients saw value in using digital biomarkers to track early signs of disease flare-ups and monitor symptoms over time. Disease Activity Mapping: Participants highlighted the importance of using a broad range of data points to reflect the complexity of PsA symptoms. Barriers: Concerns about privacy, data security, and maintaining strong connections with healthcare providers were key considerations for patients. Relevance to iPROLEPSIS The findings align with iPROLEPSIS’s goal of integrating patient-centered digital health tools into chronic disease management. This study offers important guidance on ensuring digital health innovations address real-world patient needs while maintaining trust and usability. e004699.full .pdf Download PDF • 1.55MB 1/1 PREVIOUS NEXT

< BACK Highlights from IFPA 2024 Jun 28, 2024 iPROLEPSIS at IFPA 2024 The 7th World Psoriasis & Psoriatic Arthritis Conference, held on June 27-29, 2024, brought together leading experts and researchers to discuss the latest advancements in psoriasis and psoriatic arthritis. Dr Laura Coates from the University of Oxford discussed the potential to prevent psoriatic arthritis, including the work being done in iPROLEPSIS and HIPPOCRATES IMI. 1/6 PREVIOUS NEXT